Sage/Biogen Delay Zuranolone Filing, Commercial Path Remains Unclear

 
• By Alaric DeArment

The companies will seek approval for zuranolone in MDD second-half 2022 and in PPD in first-half 2023, but that also means launch will probably happen second-half 2023.

DEPRESSION miserable depressed , Depression and its consequences, Depressed emotions concept , alone in depression - Image
Sage/Biogen provided a clear path to approval for zuranolone, though it pushed out their NDA filing to 2H22 • Source: Shutterstock

More from Neurological

More from Therapy Areas